An example of this heterogeneity was the higher level of TMB observed in MSI-H CRC with MSH2 or MSH6 mutations compared to MSI-H CRC with MLH1 or PMS2 mutations (Battaglin et al., 2018). This evidence concerns the gene MLH1 and colorectal carcinoma.